Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Author evaluates potential benefits of IAD for treating prostate cancer

'Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature' is the title of an article by P-A. Abrahamsson in the January issue of European Urology, the official journal of the European Association of Urology. The author evaluates available evidence regarding the efficacy and tolerability of intermittent androgen deprivation (IAD) and assess its value in the treatment of prostate cancer (PCa).

5 Jan 2010

Androgen receptor plays critical role in wound healing

A molecular receptor pivotal to the action of male hormones such as testosterone also plays a crucial role in the body's ability to heal, report scientists in the December issue of the Journal of Clinical Investigation.

5 Jan 2010

EPO approves Advaxis patent application for Listeria Antigens

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received notification from the European Patent Office (EPO) that Advaxis patent application 98957980.0 titled “Bacterial Vaccines Comprising Auxotrophic, Attenuated Strains of Listeria Expressing Heterologous Antigens,” has been granted and will be issued as patent #1032417

4 Jan 2010

Experimental lung cancer drug promising against brain cancer glioblastoma and prostate cancer

An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.

4 Jan 2010

Sharing Miracles: A TV program that features inspirational stories of real patients

Major League Baseball slugger Aaron Boone will be featured on January's episode of Sharing Miracles - a 30-minute public affairs television program that tells the compelling and inspirational stories of real patients. Sharing Miracles airs every week on more than 300 television stations nationwide.

31 Dec 2009

AUA experts urge to focus on urologic health conditions in upcoming year

This new year, make a resolution to improve your health and talk to your doctor about urologic conditions. Although urologic problems may seem embarrassing to talk about, these conditions are more common than you think and a delay in seeking medical attention could cause you unnecessary stress, prolong the problem and even increase your risk for a more serious condition.

30 Dec 2009

TRAP-1 may prevent cancer cell death, current research suggests

Current research suggests that TNF-receptor associated protein-1 (TRAP-1) may prevent cancer cell death. The related report by Leav et al, "Cytoprotective Mitochondrial Chaperone TRAP-1 as a Novel Molecular Target in Localized and Metastatic Prostate Cancer," appears in the January 2010 issue of the American Journal of Pathology.

30 Dec 2009

Promising results from Soligenix' RiVax vaccine against ricin toxin

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today the publication of an article in the January 2010 edition of Infection and Immunity, detailing the characteristics of several immunodominant regions of ricin A chain, the antigenic component of RiVax((TM)). RiVax((TM)) is Soligenix's vaccine to protect against exposure to ricin toxin and is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as nonhuman primate trials for efficacy.

29 Dec 2009

Study suggests routine evaluation does not predict prostate cancer

On the heels of the American Cancer Society's recent controversial response to breast and prostate cancer screenings guidelines, a new study from the Mayo Clinic has emerged analyzing the correlation between prostate-specific antigen (PSA) levels and prostate size. The study discovered that routine annual evaluation of prostate growth does not predict the development of prostate cancer.

24 Dec 2009

Interdisciplinary approach essential for treating men’s' sexual dysfunction

Modern, couple-oriented treatment for male sexual dysfunction takes the psychosocial aspects of sex into account, as well as focussing on the purely physical aspects of the problem.

24 Dec 2009

Poniard Pharmaceuticals sells common shares for $6.5 million

Poniard Pharmaceuticals today announced the sale of 3,489,728 of its common shares to Azimuth Opportunity Ltd. for net proceeds of approximately $6.5 million, or approximately $1.87 per share, under its existing committed equity financing facility with Azimuth.

23 Dec 2009

U.S. Congress approves $1.6 million for AdMeTech Foundation's research program

AdMeTech Foundation, a nonprofit organization, announced today that the U.S. Congress has approved $1.6 million for funding of its groundbreaking research program aimed at developing novel imaging technologies for early prostate cancer detection, which in turn is critical for saving lives and designing customized patient care, including the most effective and the least invasive approach.

23 Dec 2009

Four Latin American cancer patients receive treatment using RapidArc radiotherapy technology

Four cancer patients became the first in Latin America to receive treatment using a fast form of image-guided radiotherapy that potentially enables doctors to improve outcomes while extending modern care to more patients. Doctors at Hope International Centro de Radioterapia of Guatemala are now treating four patients using RapidArc® radiotherapy technology from Varian Medical Systems, one with recurring prostate cancer, one with a nasal cavity tumor, one with rectal cancer, and one with recurring glioblastoma multiforme--an aggressive type of brain tumor.

22 Dec 2009

Genome-wide study of African and African-American ancestry released by scientists

People who identify as African-American may be as little as 1 percent West African or as much as 99 percent, just one finding of a large-scale, genome-wide study of African and African-American ancestry released today.

22 Dec 2009

Novalis Tx radiosurgery platform for modern radiotherapy and radiosurgery unveiled

Slovenian Minister of Health Borut Miklavcic today officially unveiled the nation's first Novalis Tx(TM) radiosurgery platform for modern radiotherapy and radiosurgery at the Oncology Institute of Ljubljana.

22 Dec 2009

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance.

21 Dec 2009

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

Isis Pharmaceuticals, Inc. today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced non-small cell lung cancer.

21 Dec 2009

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.

21 Dec 2009

VA apologizes for faulty prostate-cancer program in Pa. but denies radiation violations

"The Department of Veterans Affairs yesterday apologized repeatedly for a prostate-cancer program that gave incorrect radiation doses to veterans for six years at its main Philadelphia hospital," The Philadelphia Inquirer reports.

18 Dec 2009

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

18 Dec 2009

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Author evaluates potential benefits of IAD for treating prostate cancer

Androgen receptor plays critical role in wound healing

EPO approves Advaxis patent application for Listeria Antigens

Experimental lung cancer drug promising against brain cancer glioblastoma and prostate cancer

Sharing Miracles: A TV program that features inspirational stories of real patients

AUA experts urge to focus on urologic health conditions in upcoming year

TRAP-1 may prevent cancer cell death, current research suggests

Promising results from Soligenix' RiVax vaccine against ricin toxin

Study suggests routine evaluation does not predict prostate cancer

Interdisciplinary approach essential for treating men’s' sexual dysfunction

Poniard Pharmaceuticals sells common shares for $6.5 million

U.S. Congress approves $1.6 million for AdMeTech Foundation's research program

Four Latin American cancer patients receive treatment using RapidArc radiotherapy technology

Genome-wide study of African and African-American ancestry released by scientists

Novalis Tx radiosurgery platform for modern radiotherapy and radiosurgery unveiled

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

VA apologizes for faulty prostate-cancer program in Pa. but denies radiation violations

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

What to know about prostate cancer eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in